Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Formulation Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

NCT03206567
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement capsules, Placebo capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

NCT04528719
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 79 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
31
States / cities
La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

NCT04124653
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06842874, Placebo, Relative Bioavailability
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy

NCT04826328
View directory record Official record
Conditions
Pain, Postoperative, Bunion
Interventions
FX301, Normal Saline
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 21, 2026, 7:14 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

NCT07644195
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TRL1068, a human monoclonal antibody
Drug
Lead sponsor
Trellis Bioscience LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

NCT00627016
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Tucson, Arizona • Anaheim, California • Garden Grove, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin and Learning in Autism

NCT01417026
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin (Trade name: Syntocinon)
Drug
Lead sponsor
Robert Schultz
Other
Eligibility
12 Years to 17 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 21, 2026, 7:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1, Nerandomilast formulation 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

NCT02720744
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
Interventions
FT218, Placebo
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 21, 2026, 7:14 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Terminated Phase 2 Interventional

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum

NCT02024581
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
10% East Indian sandalwood oil cream, Placebo Cream
Drug
Lead sponsor
ViroXis Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532

NCT01369277
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

NCT04776629
View directory record Official record
Conditions
Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
Interventions
Orticumab, Placebo
Drug
Lead sponsor
Abcentra
Industry
Eligibility
30 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Scottsdale, Arizona • Santa Monica, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Evaluation of Jarro-Dophilus EPS® Probiotic Formulations

NCT02693314
View directory record Official record
Conditions
Healthy
Interventions
Jarro-Dophilus EPS® (5 billion CFU/capsule), Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule), Placebo
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

NCT00895102
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-333 Tablet, Placebo, ABT-333 Capsule
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 21, 2026, 7:14 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941
View directory record Official record
Conditions
Neuroendocrine Tumors in Lung
Interventions
Lanreotide (Autogel formulation), Placebo, Best Supportive Care
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

NCT00797953
View directory record Official record
Conditions
Angina Pectoris
Interventions
T89
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT06375512
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ Vaccine (IN001), Placebo, Shingrix
Biological
Lead sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Industry
Eligibility
50 Years to 69 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Improving Buprenorphine Detoxification Outcomes With Isradipine

NCT01895270
View directory record Official record
Conditions
Opioid Dependence
Interventions
Isradipine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Alpha Hope Dietary Supplement on Health and Cognitive Performance

NCT05589051
View directory record Official record
Conditions
Cognitive Change
Interventions
Drink
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
40 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

NCT03176472
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
ricolinostat, Placebo
Drug
Lead sponsor
Regenacy Pharmaceuticals LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

NCT03692312
View directory record Official record
Conditions
Congenital Myotonic Dystrophy
Interventions
Tideglusib, Placebo
Drug
Lead sponsor
AMO Pharma Limited
Industry
Eligibility
6 Years to 16 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 21, 2026, 7:14 PM EDT